You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
Title |
Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies
|
---|---|
Published in |
BMC Clinical Pharmacology, March 2011
|
DOI | 10.1186/1472-6904-11-3 |
Pubmed ID | |
Authors |
Helen Tomkinson, John Kemp, Stuart Oliver, Helen Swaisland, Maria Taboada, Thomas Morris |
Abstract |
Zibotentan (ZD4054) is a specific endothelin A (ETA) receptor antagonist being investigated for the treatment of prostate cancer. As zibotentan is eliminated by renal and metabolic routes, clearance may be reduced in patients with hepatic or renal impairment, leading to greater drug exposure. |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 3% |
Unknown | 33 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 6 | 18% |
Other | 3 | 9% |
Researcher | 3 | 9% |
Student > Master | 3 | 9% |
Student > Bachelor | 2 | 6% |
Other | 5 | 15% |
Unknown | 12 | 35% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 9 | 26% |
Biochemistry, Genetics and Molecular Biology | 4 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
Agricultural and Biological Sciences | 2 | 6% |
Chemistry | 2 | 6% |
Other | 2 | 6% |
Unknown | 13 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 June 2023.
All research outputs
#7,454,951
of 22,790,780 outputs
Outputs from BMC Clinical Pharmacology
#27
of 56 outputs
Outputs of similar age
#43,779
of 121,000 outputs
Outputs of similar age from BMC Clinical Pharmacology
#3
of 3 outputs
Altmetric has tracked 22,790,780 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 56 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.1. This one is in the 33rd percentile – i.e., 33% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 121,000 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.